Zacks Research Has Pessimistic View of BMY FY2025 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a report released on Tuesday, October 21st. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings of $6.22 per share for the year, down from their prior forecast of $6.51. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s Q3 2026 earnings at $1.45 EPS.

A number of other research firms have also commented on BMY. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price for the company. in a report on Tuesday, August 5th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, October 13th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Finally, Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $57.23.

Bristol Myers Squibb Stock Down 0.4%

Bristol Myers Squibb stock opened at $44.36 on Wednesday. The firm has a 50 day simple moving average of $45.92 and a 200 day simple moving average of $47.28. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb has a 1-year low of $42.96 and a 1-year high of $63.33. The firm has a market capitalization of $90.29 billion, a price-to-earnings ratio of 17.89, a P/E/G ratio of 2.32 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. During the same quarter in the previous year, the firm posted $2.07 EPS. Bristol Myers Squibb’s revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.6%. Bristol Myers Squibb’s payout ratio is 100.00%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president directly owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.09% of the company’s stock.

Hedge Funds Weigh In On Bristol Myers Squibb

Institutional investors have recently bought and sold shares of the stock. Cerity Partners LLC lifted its holdings in Bristol Myers Squibb by 9.2% in the third quarter. Cerity Partners LLC now owns 942,270 shares of the biopharmaceutical company’s stock worth $42,496,000 after buying an additional 79,647 shares during the period. Tilson Financial Group Inc. raised its position in shares of Bristol Myers Squibb by 4.2% in the 3rd quarter. Tilson Financial Group Inc. now owns 6,445 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 259 shares in the last quarter. Mccarter Private Wealth Services LLC lifted its stake in shares of Bristol Myers Squibb by 5.0% in the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 235 shares during the period. CoreCap Advisors LLC boosted its position in shares of Bristol Myers Squibb by 14.8% during the third quarter. CoreCap Advisors LLC now owns 20,309 shares of the biopharmaceutical company’s stock valued at $916,000 after purchasing an additional 2,613 shares in the last quarter. Finally, Abundance Wealth Counselors boosted its position in shares of Bristol Myers Squibb by 5.3% during the third quarter. Abundance Wealth Counselors now owns 38,328 shares of the biopharmaceutical company’s stock valued at $1,729,000 after purchasing an additional 1,929 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.